What are the indications, dosing, and administration guidelines for lente insulin?

Lente Insulin: Clinical Overview

Lente insulin is an intermediate-acting insulin that has been largely superseded by modern insulin analogues and is no longer widely used in clinical practice, though it remains available in some formulations (particularly veterinary medicine). 1

Indications

Lente insulin is indicated for:

• Type 1 diabetes mellitus - as part of a basal-bolus regimen
• Type 2 diabetes mellitus - when oral agents fail to achieve glycemic control
• Diabetic ketoacidosis - transition from regular insulin after acute management 1

However, current guidelines strongly favor modern long-acting insulin analogues (glargine, detemir, degludec) over intermediate-acting insulins like lente and NPH for both type 1 and type 2 diabetes due to superior pharmacokinetic profiles, reduced hypoglycemia risk, and once-daily dosing convenience. 2, 3

Pharmacokinetics

Lente insulin has the following time-action profile 1:

• Onset: 30 minutes after subcutaneous injection
• Peak effect: 2-12 hours post-injection
• Duration: Up to 24 hours

The duration of lente insulin typically exceeds 24 hours (often requiring twice-daily dosing for adequate basal coverage), whereas NPH insulin's duration does not exceed 24 hours. 4

Dosing Guidelines

Initial Dosing

• Type 1 diabetes: Start with 0.4-1.0 units/kg/day total daily insulin dose, with higher amounts during puberty 2
• Type 2 diabetes:
  • Bedtime dosing: Mean requirement approximately 14 units/day 5
  • Twice-daily regimen: 0.5-0.6 units/kg/day divided into two doses 6

Administration Schedule

• Twice-daily administration is typically required for optimal glycemic control (before breakfast and dinner) 7, 8
• When mixed with regular insulin, use a 30:70 ratio (30% regular to 70% lente) as the most frequently employed mixture 7

Administration Guidelines

Mixing Considerations - CRITICAL CAVEAT

Mixing lente insulin with short-acting (regular) insulin is NOT recommended except for patients already adequately controlled on such mixtures 9. This is because:

• Regular insulin undergoes slowed absorption when mixed with lente insulin (unlike with NPH insulin) 7, 4
• Phosphate-buffered insulins (NPH) should NEVER be mixed with lente insulins 9
• Rapid-acting insulin analogues CAN be mixed with lente insulin and should be injected within 15 minutes before meals 9

Injection Technique

• Injection sites: Abdomen (fastest absorption), upper arms, buttocks, or upper thighs 1
• Rotate injection sites within the chosen area with each dose to prevent lipohypertrophy 9, 10
• Never inject into the same spot consecutively
• Avoid intramuscular injection, especially with intermediate-acting insulins, as severe hypoglycemia may result 10

Preparation

• Must be resuspended before each use - turn vial/pen up and down at least 10 times until uniformly white and cloudy 1
• Visual inspection should reveal lente insulin as uniformly cloudy (not clear) 9
• Do not use if clumping, frosting, precipitation, or color changes are present 9

Storage

• Refrigerate unopened vials (avoid temperatures <36°F or >86°F) 9
• Insulin in use may be kept at room temperature to reduce injection site irritation 9
• Avoid freezing and excessive agitation 9

Monitoring and Titration

• Titrate basal insulin based on fasting plasma glucose values 10
• Target HbA1c <7.5% for children with type 1 diabetes 10
• For type 2 diabetes, insulin is essential when HbA1c ≥10% despite optimal use of other agents 10
• Regular self-monitoring of blood glucose is integral to effective therapy 10

Safety Considerations

Hypoglycemia Risk

• Symptoms range from mild (shakiness, sweating, hunger) to severe (confusion, loss of consciousness) 1
• Treat mild hypoglycemia immediately with fast-acting carbohydrates 1
• Severe hypoglycemia requires glucagon injection or emergency medical care 1

Needle Safety

• Use shortest needles available (4mm pen needles, 6mm syringe needles) - safer, effective, less painful 10
• Single-use only recommended by manufacturers, though needle reuse is common in resource-limited settings 9, 10
• Proper disposal in puncture-resistant containers per local regulations 9

Modern Context

The introduction of insulin glargine in 2000 marked the decline of the 50-year era of intermediate-acting insulins (NPH and lente) 3. Long-acting analogues offer:

• True once-daily dosing
• More physiologic basal insulin coverage
• Lower nocturnal hypoglycemia risk compared to NPH/lente
• Reduced need for frequent blood glucose monitoring 3

While lente insulin remains effective when used appropriately 11, current standard of care strongly favors rapid-acting insulin analogues combined with long-acting basal analogues for multiple daily injection regimens 2.